200 related articles for article (PubMed ID: 28544769)
1. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.
Vilar-Gomez E; Calzadilla-Bertot L; Friedman SL; Gra-Oramas B; Gonzalez-Fabian L; Lazo-Del Vallin S; Diago M; Adams LA
Liver Int; 2017 Dec; 37(12):1887-1896. PubMed ID: 28544769
[TBL] [Abstract][Full Text] [Related]
2. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
[TBL] [Abstract][Full Text] [Related]
5. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease.
Song DS; Chang UI; Kang SG; Song SW; Yang JM
Gut Liver; 2019 Nov; 13(6):658-668. PubMed ID: 30970434
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis.
Ismaiel A; Leucuta DC; Popa SL; Fagoonee S; Pellicano R; Abenavoli L; Dumitrascu DL
Panminerva Med; 2021 Dec; 63(4):508-518. PubMed ID: 33165307
[TBL] [Abstract][Full Text] [Related]
10. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
11. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
[TBL] [Abstract][Full Text] [Related]
12. Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis.
Manka P; Bechmann L; Best J; Sydor S; Claridge LC; Coombes JD; Canbay A; Moeller L; Gerken G; Wedemeyer H; Syn WK
Dig Dis Sci; 2019 Aug; 64(8):2351-2358. PubMed ID: 31155687
[TBL] [Abstract][Full Text] [Related]
13. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
[TBL] [Abstract][Full Text] [Related]
14. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.
Lykiardopoulos B; Hagström H; Fredrikson M; Ignatova S; Stål P; Hultcrantz R; Ekstedt M; Kechagias S
PLoS One; 2016; 11(12):e0167776. PubMed ID: 27936091
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
Vilar-Gomez E; Chalasani N
J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.
Vilar-Gomez E; Yasells-Garcia A; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Villa-Jimenez O; Friedman SL; Diago M; Romero-Gomez M
Hepatology; 2016 Jun; 63(6):1875-87. PubMed ID: 26849287
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic Fatty liver disease.
Mansoor S; Collyer E; Alkhouri N
Curr Gastroenterol Rep; 2015 Jun; 17(6):23. PubMed ID: 26031832
[TBL] [Abstract][Full Text] [Related]
18. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
[TBL] [Abstract][Full Text] [Related]
19. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M
Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
[TBL] [Abstract][Full Text] [Related]
20. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
McPherson S; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2014 May; 60(5):1055-62. PubMed ID: 24445215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
